ApoB can also serve as an important target for the prevention and treatment of ASCVD, particularly in patients with mild to moderate hypertriglyceridemia (2–5.6 mmol/L), diabetes, obesity, or metabolic syndrome, or in patients with LDL-C levels < 1.8 mmol/L [25]. This evidence concerns the gene APOB and obesity due to melanocortin 4 receptor deficiency.